Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Expected to Rise, Chardan Capital Analyst Says

Taysha Gene Therapies (NASDAQ:TSHA - Free Report) had its price target boosted by Chardan Capital from $7.00 to $9.00 in a research report released on Thursday,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

Other analysts have also issued research reports about the company. Canaccord Genuity Group lifted their target price on Taysha Gene Therapies from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Friday, May 16th. Needham & Company LLC reissued a "buy" rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a report on Thursday, April 10th. JMP Securities reissued a "market outperform" rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a report on Monday, April 28th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Monday, April 28th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $7.00.

Taysha Gene Therapies Stock Down 1.5%

TSHA stock traded down $0.04 on Thursday, reaching $2.71. 5,622,850 shares of the company traded hands, compared to its average volume of 3,008,932. Taysha Gene Therapies has a one year low of $1.05 and a one year high of $4.32. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The company has a market cap of $581.73 million, a P/E ratio of 4.30 and a beta of 0.90. The firm has a fifty day simple moving average of $1.92 and a 200-day simple moving average of $1.91.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.08) EPS for the quarter, hitting analysts' consensus estimates of ($0.08). The business had revenue of $2.30 million during the quarter, compared to analyst estimates of $1.48 million. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. During the same quarter last year, the company earned ($0.10) EPS. Research analysts anticipate that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of institutional investors and hedge funds have recently modified their holdings of the company. Avoro Capital Advisors LLC boosted its stake in shares of Taysha Gene Therapies by 7.2% in the 4th quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company's stock worth $34,600,000 after buying an additional 1,349,999 shares during the last quarter. Octagon Capital Advisors LP boosted its stake in shares of Taysha Gene Therapies by 2.4% in the 1st quarter. Octagon Capital Advisors LP now owns 10,700,000 shares of the company's stock worth $14,873,000 after buying an additional 250,000 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Taysha Gene Therapies by 7.8% in the 4th quarter. Vanguard Group Inc. now owns 8,906,764 shares of the company's stock worth $15,409,000 after buying an additional 641,305 shares during the last quarter. Adage Capital Partners GP L.L.C. purchased a new position in shares of Taysha Gene Therapies in the 4th quarter worth $8,650,000. Finally, Geode Capital Management LLC lifted its position in Taysha Gene Therapies by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company's stock valued at $6,182,000 after purchasing an additional 9,591 shares in the last quarter. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.